

Opioid Use Disorder

Samuel Martin, MD

Assistant Clinical Professor

Department of Psychiatry and Behavioral Sciences
Oklahoma State University Center for Health Sciences


Disclosures

- I have nothing to disclose

Objectives

- Review past and recent trends in the current opioid epidemic
- Briefly review evidence based treatments for opioid use disorder
 - Psychotherapies
 - Medication assisted treatments (MAT)
- Discuss the benefits of medication assisted treatments

The Opioid Epidemic



Center for Disease Control and Prevention. WONDER. <http://wonder.cdc.gov/mcd.html>.


Psychotherapy for Opioid Use Disorder

- Cognitive-behavioral therapy/relapse prevention therapy
- Motivational enhancement therapy
- Contingency management interventions


FDA Approved Medications for Opioid Addiction Treatment

- Mu Opioid Receptor Full Agonist
 - Methadone (requires administration in opioid treatment program)
- Mu Opioid Receptor Partial Agonist
 - Buprenorphine and buprenorphine/naloxone (requires waiver to use)
- Mu Opioid Receptor Antagonist
 - Extended Release Naltrexone

Full Agonist vs Partial Agonist vs Antagonist




Abstinence without Medication Assisted Treatment



Hunt, WA. Journal of Clinical Psychology. 1971, 27(4): 455-456.

Decreased Mortality with Medication Assisted Treatment



Improved Outcomes with Medication Assisted Treatment

- Decreased mortality
- Decreased use of opioids
- Increased treatment retention
- Decreased opioid cravings
- Improved quality of life

References

- Centers for Disease Control and Prevention. Wide-ranging online data for epidemiologic research (WONDER)
<http://wonder.cdc.gov/mcd.html>. Accessed 04/12/2019.
- Dupouy J, Palmaro A, Fatseas M, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study. *Annals of Family Medicine*. 2017, 15(4): 355-358.
- Hunt WA, Barnett LW, Branch LG. Relapse rates in addiction programs. *Psychology*. 1971, 27(4): 455-456.

References

- Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. *Drugs*. 2009, 69: 577-607.
- Ries RK, Fiellin DA, Miller SC, et al. *The ASAM Principles of Addiction Medicine*, 5th Ed. 2014. Philadelphia, PA: Wolters Kluwer Health.